We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Nevada’s Department of Health and Human Services sent penalty letters last week to 21 drugmakers — totaling $17.4 million — for failing to file pricing reports on their diabetes drugs. Read More
Attorneys general from than two dozen states pushed back against Purdue Pharma’s plan to pay employees $38 million in bonuses, in a joint filing with the U.S. Bankruptcy Court in the Southern District of New York. Read More
A report from the White House Council of Economic Advisors on measuring prescription drug prices finds that the CPI Prescription Drug Index (CPI-Rx) prepared by the Bureau of Labor Statistics is “the best available summary measure” of the prescription drug price changes — but some groups claim it’s flawed because it leaves out new, expensive drugs. Read More
In an usual move, the Institute for Clinical and Economic Review (ICER) quickly withdrew a draft report that questioned the cost-effectiveness of three rheumatoid arthritis treatments, saying that it needs to reconsider its approach. Read More